TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9803198
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for cough or bronchitis
Study: 9803198
Drug: Empiric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric treatment for pharyngitis
Study: 9803198
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for common cold
Study: 3049216
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human alpha-interferon therapy (4-month duration)
Study: 3049216
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human alpha-interferon therapy
Study: 31326433
Drug: Glepaglutide 1
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glepaglutide 1 mg
Study: 28482869
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (200 mg per day in 100 ml 0.9% sodium chloride)
Study: 28482869
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous fumarate (200 mg per day)
Study: 25501671
Drug: Brivaracetam 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 150 mg/day
Study: 25501671
Drug: Brivaracetam 5
Normalized name: brivaracetam 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 5 mg/day
Study: 15706200
Drug: Art therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art therapy intervention
Study: 16490980
Drug: Topical povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical povidone-iodine (Betadine) with compression bandages
Study: 16490980
Drug: Topical povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical povidone-iodine (Betadine) without compression bandages
Study: 16490980
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (amoxicillin)
Study: 16490980
Drug: Topical povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical povidone-iodine (Betadine)
Study: 11194245
Drug: Repaglinide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (0.5 mg)
Study: 24365552
Drug: Generic three-drug
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic three-drug FDC formulation (3FDC)
Study: 24365552
Drug: 3FDC reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3FDC reference formulation
Study: 23405793
Drug: Compound Xuanju
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Xuanju Capsule plus apomorphine hydrochloride
Study: 20461810
Drug: Ropinirole prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole prolonged release (2-24 mg/day)
Study: 12728300
Drug: L-tryptophan infusion
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan infusion
Study: 9061426
Drug: Irrigating fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigating fluid absorption during TURP
Study: 9061426
Drug: Choice of
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of crystalloid or colloid solution for intravenous fluid supplementation
Study: 6360031
Drug: 10 to
Normalized name: RE-10 Topical Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 to 15 mg oral physostigmine daily
Study: 19854793
Drug: Clonidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.5 microg/kg bolus, followed by continuous infusion at 1‐2 microg/kg/h)
Study: 15617992
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HD-CT) using the CMA regimen (Mitoxantrone, Cyclophosphamide, Melphalan)
Study: 8649056
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (CT)
Study: 10362194
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ACE inhibitors
Study: 10362194
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors without aspirin
Study: 10362194
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ACE inhibitors in congestive heart failure patients
Study: 10362194
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors without aspirin in congestive heart failure patients
Study: 7589340
Drug: 13‐cis‐retinoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13‐cis‐retinoic acid (10 to 60 mg/m2/daily) administered in combination with vitamin E for 3 months to 5 years
Study: 19387807
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A - Enoxaparin 1 mg/kg x ten doses
Study: 19387807
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B - Enoxaparin 1 mg/kg x six doses
Study: 19387807
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C - Enoxaparin 0.5 mg/kg x six doses
Study: 16965205
Drug: Concomitant psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant psychotropic medications (CPMs) - antidepressants
Study: 16965205
Drug: Concomitant psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant psychotropic medications (CPMs) - mood stabilizers
Study: 16965205
Drug: Concomitant psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant psychotropic medications (CPMs) - modafinil and trazodone
Study: 16965205
Drug: Concomitant psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant psychotropic medications (CPMs) - sleeping medications
Study: 9523960
Drug: Initial injection
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial injection into the midcarpal and distal radioulnar joints
Study: 9523960
Drug: Initial injection
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial injection into the radiocarpal joint
Study: 7660509
Drug: Oral face‐to‐face
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral face‐to‐face interview
Study: 23571304
Drug: directive counseling
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: directive counseling and sound therapy using conventional sound generators
Study: 23571304
Drug: standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care as administered in the military
Study: 17159758
Drug: 15 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL/kg of hydroxyethyl starch 6% (Group A)
Study: 15571637
Drug: comicronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: comicronized fenofibrate 200 mg daily
Study: 9763251
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine and smoking cessation
Study: 26096013
Drug: Non-invasive ventilation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive ventilation during airway clearance treatments
Study: 17720102
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=27) received dietary advice to match intake with 1.2 g of protein per kg of ideal body weight and 25 cal/kg ideal body weight.
Study: 17720102
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n=28) received dietary advice to match energy intake with estimated total energy expenditure, with a protein intake of 0.8 to 1.0 g/kg.
Study: 14728998
Drug: Hormonal replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal replacement therapy (androgens)
Study: 9833603
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 30 g L-arginine
Study: 9833603
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 6 g L-arginine
Study: 9833603
Drug: Oral ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ingestion of 6 g L-arginine
Study: 7867963
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of psycho‐active medications
Study: 7867963
Drug: Impaired orientation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired orientation, psycho‐active drug use, evidence of stroke, and impaired performance in the 'Get‐up‐and‐go' test
Study: 561495
Drug: Dexamethasone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (12 mg per day orally for three successive days)
Study: 24863414
Drug: Oral antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidant cocktail (vitamin C, 1000 mg; vitamin E, 600 IU; alpha‐lipoic acid, 600 mg)
Study: 24318038
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.3 g/kg for 7 days)
Study: 18769961
Drug: 100 microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg/day of transdermal 17beta‐estradiol for 4 weeks
Study: 17934931
Drug: promestriene 10
Normalized name: promestriene 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: promestriene 10 mg daily, by vaginal capsule, for 21 days before the operation
Study: 17934931
Drug: TVT (Tension‐free
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVT (Tension‐free Vaginal Tape) surgical procedure without pharmacological preparation
Study: 3071615
Drug: Ceftriaxone (CTRX)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (CTRX) 10 mg/kg
Study: 3071615
Drug: Ceftriaxone (CTRX)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (CTRX) 20 mg/kg
Study: 24105750
Drug: Interferon α-2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon α-2b, 3 MU three times weekly for 18 months
Study: 17364603
Drug: Transdermal Estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Estrogens
Study: 17364603
Drug: Oral Estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Estrogens
Study: 17364603
Drug: Transdermal Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal Placebo
Study: 9840216
Drug: Experimental sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental sustained release tablet containing dextromethorphan hydrobromide (DXP‐HBr)
Study: 9840216
Drug: Marketed sustained
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed sustained release DXP‐HBr suspension
Study: 25532503
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg)
Study: 3598997
Drug: Nifedipine, 10
Normalized name: Nifedipine, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 10 mg sublingually
Study: 30084233
Drug: 0.0625 mg
Normalized name: digoxin 0.0625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625 mg linaclotide
Study: 30084233
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg linaclotide
Study: 30084233
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg linaclotide
Study: 30084233
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg linaclotide
Study: 17620510
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of bone marrow-derived progenitor cells (BMCs)
Study: 15668818
Drug: Risperidone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1 to 4 mg/day, mean dosage 1.45±0.08 mg/day)
Study: 15668818
Drug: Risperidone (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (open-label treatment after 4 weeks)
Study: 15668818
Drug: Placebo (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (initial treatment for 4 weeks)
Study: 11876001
Drug: Antibacterial therapy
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial therapy (ABT) in 30-34 week neonates
Study: 11876001
Drug: No antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibacterial therapy (ABT) in 30-34 week neonates
Study: 11876001
Drug: Antibacterial therapy
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial therapy (ABT) in neonates < 30 weeks
Study: 7586114
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg at 21:00 and placebo at 06:30 (150/0)
Study: 7586114
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg at 21:00 and 06:30 (150/150)
Study: 7586114
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg at 21:00 and placebo at 06:30 (300/0)
Study: 7586114
Drug: Placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at 21:00 and nizatidine 300 mg at 06:30 (0/300)
Study: 7586114
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg at 21:00 and 06:30 (300/300)
Study: 1703655
Drug: Foreign drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foreign drug
Study: 28131530
Drug: Vancomycin dosing
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin dosing algorithm based on estimated glomerular filtration rate from cystatin C levels (eGFRcr‐cys)
Study: 28131530
Drug: Vancomycin dosing
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin dosing algorithm based on estimated creatinine clearance (eCLcr) using the Cockcroft‐Gault formula
Study: 24169062
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol at 320 micrograms once daily
Study: 9767357
Drug: n‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 fatty acids (4.8 g daily)
Study: 9767357
Drug: Antioxidants (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (150 mg of vitamin C, 75 mg of vitamin E and 15 mg of beta‐carotene daily)
Study: 8311284
Drug: Neostigmine 0.015,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.015, 0.03, 0.045, or 0.06 mg/kg
Study: 8311284
Drug: Edrophonium 0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.125, 0.25, 0.75, or 1 mg/kg
Study: 7942250
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration
Study: 31595608
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 58.8 mg
Study: 27055417
Drug: Once-daily colchicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily colchicine dosage
Study: 27055417
Drug: Twice-daily colchicine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily colchicine dosage
Study: 23608920
Drug: Dabrafenib administered
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib administered in nonmicronized form (larger particle size) under fasting conditions
Study: 23608920
Drug: Dabrafenib administered
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib administered in HPMC capsules
Study: 23608920
Drug: Dabrafenib administered
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib administered in gelatin capsules
Study: 23608920
Drug: Dabrafenib administered
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib administered under fasting conditions
Study: 6789008
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) at 35 calories/kgm/day for at least 14 days postoperatively.
Study: 31441801
Drug: Low-dose midazolam
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose midazolam
Study: 8375835
Drug: Recent regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent regular use criteria (any past period of daily or weekly use plus any use during the 30 days before hospitalization)
Study: 23919920
Drug: Synbiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic mixture (two Lactobacillus strains, one Bifidobacterium strain, one Propionibacterium strain and galacto‐oligosaccharides (32 g/l))
Study: 23921307
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg/d)
Study: 23921307
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg/d)
Study: 18758308
Drug: Maintenance irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance irinotecan therapy (100 mg/m IV on days 1, 8, and 15, every 4 weeks up to six cycles)
Study: 10803042
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists and angiotensin-converting-enzyme inhibitors
Study: 10803042
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive drugs (beta-blockers or diuretics)
Study: 1992963
Drug: 14 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 mg/kg per day of oral cyclosporine for 4 weeks (Group 1)
Study: 1992963
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg per day of oral cyclosporine for 1 to 3 months (Group 2)
Study: 1992963
Drug: Combined data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined data for both groups for the first 4 weeks of therapy
Study: 25096168
Drug: Weekly paclitaxel/carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly paclitaxel/carboplatin (PCw) - paclitaxel 90mg/m², cisplatin 70mg/m² or carboplatin AUC 4
Study: 25096168
Drug: Three-weekly paclitaxel/carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-weekly paclitaxel/carboplatin (PC3w) - paclitaxel 175mg/m², cisplatin 75mg/m² or carboplatin AUC 6
Study: 21696933
Drug: E0.25 (esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E0.25 (esmolol 0.25 mg/kg)
Study: 21696933
Drug: E0.5 (esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E0.5 (esmolol 0.5 mg/kg)
Study: 21696933
Drug: E1.0 (esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E1.0 (esmolol 1.0 mg/kg)
Study: 19563327
Drug: IMZ implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMZ implant system (two-stage cylinder type)
Study: 15191587
Drug: Brånemark implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark implant system (two-stage screw type)
Study: 19563327
Drug: ITI implant
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI implant system (one-stage screw type)
Study: 11587240
Drug: Structured care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured care outpatient treatment program
Study: 7872284
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (1 g/day)
Study: 2143129
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) infusion at 0.25 micrograms/min
Study: 2143129
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) infusion at 2.0 micrograms/min
Study: 332184
Drug: 4 gm
Normalized name: Olpruva 4 GM Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 gm aspirin daily for 5 days
Study: 29342509
Drug: Combination format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination format (numbers + IA + BS)
Study: 18492750
Drug: Cholecalciferol (D3)
Normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (D3) oral (os)
Study: 18492750
Drug: Ergocalciferol (D2)
Normalized name: ERGOCALCIFEROL (D2) 200MCG/ML ORAL DROPS
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol (D2) oral (os)
Study: 18492750
Drug: Cholecalciferol (D3)
Normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (D3) intramuscular (im)
Study: 18492750
Drug: Ergocalciferol (D2)
Normalized name: ERGOCALCIFEROL (D2) 200MCG/ML ORAL DROPS
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ergocalciferol (D2) intramuscular (im)
Study: 9753533
Drug: Patient Competency
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Competency Rating Scale (PCRS) administered to TBI patients
Study: 9753533
Drug: Patient Competency
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Competency Rating Scale (PCRS) administered to controls
Study: 8164820
Drug: Diphenhydramine 1
Normalized name: diphenhydramine 18.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 1 mg/kg (young controls)
Study: 3047336
Drug: Androgen priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen priming for three days before and on the day of chemotherapy
Study: 794558
Drug: 25-hydroxycholecalciferol (25-(OH)D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxycholecalciferol (25-(OH)D3) 25 to 50 mug/day with calcium supplementation (0.5 to 1.5 g/day)